Resources
14 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 2/10/2021 (updated 4/4/2024)
The Opioid Response Network is making available a new dental curriculum on SBIRT (screening, brief intervention and referral to treatment), an evidence-based approach to managing patients with or at risk of developing a substance use disorder (SUD).
The curriculum was developed for dentists by the ORN grant through a collaboration with the American Academy of Addiction Psychiatry and the Division on Substance Use Disorders, Columbia University Irving Medical Center/NYSPI.
Posted 10/26/2021 (updated 4/3/2024)
Posted 9/22/2021 (updated 4/3/2024)
PCSS's PCSS-Implementation (PCSS-I) initiative is here to support clinicians and their clinical programs by implementing medications for opioid use disorder (MOUD) into your practice.
PCSS-I has clinical and implementation experts as PCSS-I Facilitators available to work with you and your team to develop strategies tailored specifically to support your needs. There is no cost to participate.
Posted 10/23/2020 (updated 4/3/2024)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.
Posted 3/15/2024 (updated 3/28/2024)
Clinical experts from the Providers Clinical Support System (PCSS) created the Substance Use Disorder 101 Core Curriculum for Healthcare Professionals. With the addition of two new module topics, the 23 modules in this 2023 curriculum provide an overview of evidence-based practices in the prevention, identification, and treatment of substance use disorders and co-occurring medical and psychiatric conditions for a variety of populations.
Posted 1/17/2023 (updated 3/27/2024)
The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.
Posted 3/29/2023 (updated 3/27/2024)
The University of Rochester Medicine Recovery Center of Excellence is offering free trainings to provide guidance on evidence-based strategies to work through resistance and encourage help-seeking behavior. Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS) is an evidence-based technique to encourage help seeking among those in need.